8-K: MoonLake Immunotherapeutics Announces Positive Clinical Trial Results and Pipeline Expansion

MoonLake Immunotherapeutics reported significant improvements with their Nanobody sonelokimab in psoriatic arthritis and announced the commencement of Phase 3 trials in hidradenitis suppurativa.

Summary

• MoonLake Immunotherapeutics announced positive 24-week data from the ARGO trial of sonelokimab in psoriatic arthritis (PsA), showing significant improvements across key outcomes.
• Approximately 60% of patients achieved an ACR50 response at week 24, with unprecedented multi-domain responses across joints and skin.
• Up to 52% of patients achieved ACR50+PASI100 and up to 61% achieved Minimal Disease Activity (MDA).
• Monthly maintenance with 60mg or 120mg doses of sonelokimab showed leading responses above the TNF reference arm.
• The 120mg dose provided added benefit for specific patient subgroups.
• The discontinuation rate was low at around 5%, and the safety profile was consistent with previous studies.
• MoonLake intends to commence Phase 3 trials in hidradenitis suppurativa (HS) in Q2 2024, with top-line primary endpoint data expected as early as mid-2025.
• Real-world data indicates that at least 2 million Americans have been diagnosed with HS as of 2023, representing a market opportunity exceeding $10 billion by 2035.
• The company will also commence four additional clinical trials of sonelokimab across dermatology and rheumatology, including trials in palmo-plantar pustulosis, juvenile HS, and seronegative spondyloarthritis.

Sentiment

Score: 9

Explanation: The document is highly positive, highlighting strong clinical results, pipeline expansion, and a large market opportunity. The management's comments and the overall tone suggest a high level of confidence in the company's future prospects.

Positives

• Sonelokimab showed significant improvements in PsA, with high rates of ACR50, PASI100, and MDA responses.
• The drug has a favorable safety profile with a low discontinuation rate.
• The company is expanding its pipeline with new trials in multiple indications.
• Regulatory bodies support the Phase 3 program for sonelokimab in HS.
• Real-world data supports a large market opportunity for HS treatment.
• The company has strong financials to support its development plans.

Negatives

• The document does not explicitly state any negatives, but it does mention that sonelokimab is still investigational and not yet approved for use in any indication.
• The document notes that current biologics for HS have low penetration and high dropout rates, highlighting the need for better therapies.

Risks

• The document includes a cautionary statement regarding forward-looking statements, noting that actual results could differ materially from those anticipated due to various risks and uncertainties.
• There are risks associated with the company's limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials.
• The document mentions that new risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

Future Outlook

MoonLake plans to commence Phase 3 trials in both HS and PsA before the end of the year and is expanding its development pipeline with the aim of elevating care with its next-level therapies via truly innovative clinical trials. The company expects top-line primary endpoint data from the HS Phase 3 trial as early as mid-2025.

Management Comments

• Kristian Reich, MD, PhD, Founder and Chief Scientific Officer at MoonLake, stated that the positive results from the ARGO trial reinforce the advantages of using a smaller biologic with albumin-binding capability to effectively inhibit IL-17F in addition to IL-17A.
• Professor Joseph F. Merola, MD, MMSc, Founding President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN), noted the vital need for new treatment options for psoriatic arthritis and expressed encouragement at the high clinical responses observed with sonelokimab.
• Professor Kenneth B. Gordon, Chair of Dermatology at the Medical College of Wisconsin, commented that the positive data for sonelokimab across chronic inflammatory indications is raising the bar on the level of outcomes that can be achieved for patients.
• Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, stated that the robust data shows sonelokimab has the potential to be a best-in-class product in the fast-growing inflammation field.

Industry Context

This announcement is significant as it highlights the potential of a novel Nanobody therapy in addressing unmet needs in inflammatory diseases. The positive results and pipeline expansion position MoonLake as a strong competitor in the biotechnology space, particularly in the treatment of PsA and HS, where current therapies have limitations.

Comparison to Industry Standards

• The ARGO trial results for sonelokimab in PsA showed higher ACR50 and PASI responses compared to adalimumab, an active reference arm, and also higher when indirectly compared to competitors using the same active reference arm as a standard.
• In the HS space, the MIRA trial showed higher HiSCR75 responses compared to previous trials with adalimumab and secukinumab, indicating a potential for improved efficacy.
• The company is also pursuing innovative trial designs, such as the use of MRI-PET imaging in axSpA trials, which could set new standards for measuring treatment outcomes.
• The document notes that Bimekizumab (Bimzelx) has achieved leadership in the dynamic market share of the IL-17 class, with share reaching ~40%, indicating a competitive landscape where MoonLake is aiming to differentiate itself with its unique Nanobody technology.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results and pipeline expansion.
• Patients with PsA and HS may benefit from the development of new and more effective treatment options.
• Employees may be motivated by the company's progress and growth prospects.
• The company's success could lead to increased revenue and market share, benefiting suppliers and other stakeholders.

Next Steps

• MoonLake will commence Phase 3 trials in HS in Q2 2024.
• The company will initiate four additional clinical trials of sonelokimab across dermatology and rheumatology.
• Full results from the ARGO trial will be submitted for publication in a peer-reviewed medical journal.
• The company will continue to develop and expand its pipeline of indications for sonelokimab.

Key Dates

Keywords

sonelokimab, psoriatic arthritis, hidradenitis suppurativa, Nanobody, clinical trials, IL-17A, IL-17F, dermatology, rheumatology, inflammatory diseases